Evaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer
Ataxia telangiectasia and Rad3-related (ATR) threonine serine kinase is one of the key elements in orchestrating the DNA damage response (DDR). As such, inhibition of ATR can amplify the effects of chemo- and radiation-therapy, and several ATR inhibitors (ATRi) have already undergone clinical testing in cancer. For more accurate patient selection, monitoring and staging, real-time in vivo imaging of ATR could be invaluable; the development of appropriate imaging agents has remained a major challenge.
Source: Nuclear Medicine and Biology - Category: Nuclear Medicine Authors: Giuseppe Carlucci, Brandon Carney, Ahmad Sadique, Axel Vansteene, Jun Tang, Thomas Reiner Source Type: research
More News: Ataxia | Biology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Neurology | Nuclear Medicine | Radiation Therapy | Radiology